Publication: Diagnosis and management of fetal autoimmune atrioventricular block
Issued Date
2020-01-01
Resource Type
ISSN
11791411
Other identifier(s)
2-s2.0-85089675388
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Women's Health. Vol.12, (2020), 633-639
Suggested Citation
Wirada Hansahiranwadee Diagnosis and management of fetal autoimmune atrioventricular block. International Journal of Women's Health. Vol.12, (2020), 633-639. doi:10.2147/IJWH.S257407 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/59276
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Diagnosis and management of fetal autoimmune atrioventricular block
Author(s)
Other Contributor(s)
Abstract
© 2020 Hansahiranwadee. Autoimmune congenital atrioventricular block (CAVB) has been extensively studied in recent decades. The American Heart Association published guidelines for monitoring pregnant women with anti-Ro/Sjögren’s syndrome antigen A (SSA) or antiLa/Sjögren’s syndrome antigen B (SSB) autoantibodies, which are considered to increase the risk of CAVB. Information about the natural history of the disease in utero has contributed to the detection of fetuses with CAVB in the treatable stage. Hydroxychloroquine (HCQ) may be used to prevent CAVB. The lack of large randomized control trials is a major drawback to fully confirm the benefits of fluorinated steroids such as dexamethasone. Although, when combined with a β-sympathomimetic agent, the outcome of administering a fluorinated steroid in complete CAVB is still controversial. Novel treatments targeting the immunological process might prevent the recurrence of CAVB in pregnant women with previously affected children.